BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

867 related articles for article (PubMed ID: 23510087)

  • 1. Conjugation of a Ru(II) arene complex to neomycin or to guanidinoneomycin leads to compounds with differential cytotoxicities and accumulation between cancer and normal cells.
    Grau-Campistany A; Massaguer A; Carrion-Salip D; Barragán F; Artigas G; López-Senín P; Moreno V; Marchán V
    Mol Pharm; 2013 May; 10(5):1964-76. PubMed ID: 23510087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transferrin serves as a mediator to deliver organometallic ruthenium(II) anticancer complexes into cells.
    Guo W; Zheng W; Luo Q; Li X; Zhao Y; Xiong S; Wang F
    Inorg Chem; 2013 May; 52(9):5328-38. PubMed ID: 23586415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer activity of ruthenium(II) arene complexes bearing 1,2,3,4-tetrahydroisoquinoline amino alcohol ligands.
    Chelopo MP; Pawar SA; Sokhela MK; Govender T; Kruger HG; Maguire GE
    Eur J Med Chem; 2013 Aug; 66():407-14. PubMed ID: 23827181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands.
    Zhang Y; Zheng W; Luo Q; Zhao Y; Zhang E; Liu S; Wang F
    Dalton Trans; 2015 Aug; 44(29):13100-11. PubMed ID: 26106875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer activity of tetracationic arene ruthenium metalla-cycles.
    Barry NP; Edafe F; Therrien B
    Dalton Trans; 2011 Jul; 40(27):7172-80. PubMed ID: 21660364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
    Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
    Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipophilicity-antiproliferative activity relationship study leads to the preparation of a ruthenium(II) arene complex with considerable in vitro cytotoxicity against cancer cells and a lower in vivo toxicity in zebrafish embryos than clinically approved cis-platin.
    Haghdoost M; Golbaghi G; Létourneau M; Patten SA; Castonguay A
    Eur J Med Chem; 2017 May; 132():282-293. PubMed ID: 28371640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Picolinate ruthenium(II)-arene complex with in vitro antiproliferative and antimetastatic properties: comparison to a series of ruthenium(II)-arene complexes with similar structure.
    Gligorijević N; Aranđelović S; Filipović L; Jakovljević K; Janković R; Grgurić-Šipka S; Ivanović I; Radulović S; Tešić ZLj
    J Inorg Biochem; 2012 Mar; 108():53-61. PubMed ID: 22266461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate.
    Meier SM; Novak M; Kandioller W; Jakupec MA; Arion VB; Metzler-Nolte N; Keppler BK; Hartinger CG
    Chemistry; 2013 Jul; 19(28):9297-307. PubMed ID: 23712572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective cytotoxic Ru(II) arene Cp* complex salts [R-PhRuCp*](+)X(-) for X = BF4(-), PF6(-), and BPh4(-).
    Loughrey BT; Healy PC; Parsons PG; Williams ML
    Inorg Chem; 2008 Oct; 47(19):8589-91. PubMed ID: 18783214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, characterization and biological evaluation of cationic organoruthenium(ii) fluorene complexes: influence of the nature of the counteranion.
    Haghdoost MM; Golbaghi G; Guard J; Sielanczyk S; Patten SA; Castonguay A
    Dalton Trans; 2019 Sep; 48(35):13396-13405. PubMed ID: 31432885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.
    Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ
    Inorg Chem; 2006 Oct; 45(22):9006-13. PubMed ID: 17054361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
    Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
    J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular delivery of pyrenyl-arene ruthenium complexes by a water-soluble arene ruthenium metalla-cage.
    Furrer MA; Schmitt F; Wiederkehr M; Juillerat-Jeanneret L; Therrien B
    Dalton Trans; 2012 Jun; 41(24):7201-11. PubMed ID: 22506276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiophenolato-bridged dinuclear arene ruthenium complexes: a new family of highly cytotoxic anticancer agents.
    Gras M; Therrien B; Süss-Fink G; Zava O; Dyson PJ
    Dalton Trans; 2010 Nov; 39(42):10305-13. PubMed ID: 20890536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
    Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
    Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel ruthenium complexes ligated with 4-anilinoquinazoline derivatives: synthesis, characterisation and preliminary evaluation of biological activity.
    Ji L; Zheng W; Lin Y; Wang X; Lü S; Hao X; Luo Q; Li X; Yang L; Wang F
    Eur J Med Chem; 2014 Apr; 77():110-20. PubMed ID: 24631730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and cellular impact of diene-ruthenium(II) complexes: a new class of organoruthenium anticancer agents.
    Kasper C; Alborzinia H; Can S; Kitanovic I; Meyer A; Geldmacher Y; Oleszak M; Ott I; Wölfl S; Sheldrick WS
    J Inorg Biochem; 2012 Jan; 106(1):126-33. PubMed ID: 22115828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L- and D-proline thiosemicarbazone conjugates: coordination behavior in solution and the effect of copper(II) coordination on their antiproliferative activity.
    Milunovic MN; Enyedy É; Nagy NV; Kiss T; Trondl R; Jakupec MA; Keppler BK; Krachler R; Novitchi G; Arion VB
    Inorg Chem; 2012 Sep; 51(17):9309-21. PubMed ID: 22889304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and cytotoxic activities of organometallic Ru(II) diamine complexes.
    Kavukcu SB; Şahin O; Seda Vatansever H; Kurt FO; Korkmaz M; Kendirci R; Pelit L; Türkmen H
    Bioorg Chem; 2020 Jun; 99():103793. PubMed ID: 32278205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.